CytoReason Licenses IBD Disease Model to Sanofi in Expanded Alliance
Sanofi, CytoReason expanding collaboration to AI for inflammatory bowel disease targets
CytoReason and Sanofi take collaboration into IBD
Sanofi inks deal to expand AI use for drug discovery
Sanofi extends deal with CytoReason
Sanofi Extends Deal with CytoReason to License IBD Disease Modeling
2023 Predictions – the Good, the Bad, and the Ugly
Using Computational Disease Models and Synthetic Clinical Trials for Drug Research and Development with David Harel CytoReason
Executives Reunite at JPM as Biotech Kicks Off 2023
The Rise of Computational Biology in Biopharma
